TrialGynecologic oncology2015

Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.

Vicky Makker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.